Clinical development of gene therapy for colorectal cancer

Nature Reviews Cancer

Volumn 3, Issue 8, 2003, Pages 615-622

  Kerr, David ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; B7 ANTIGEN; BEVACIZUMAB; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CITUXIMAB; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOSINE DEAMINASE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUCYTOSINE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; NITROIMIDAZOLE; OXIDOREDUCTASE; PROTEIN P53; TELOMERASE; THYMIDINE KINASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ENZYME; PRODRUG;

ANIMAL MODEL; ANTIGEN EXPRESSION; CANARYPOX VIRUS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE REPLACEMENT THERAPY; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOGENETICS; LIVER METASTASIS; LIVER TOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MYCOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TRANSGENE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIROTHERAPY; VIRUS RECOMBINANT; VIRUS REPLICATION; BIOLOGICAL MODEL; COLORECTAL TUMOR; GENE VECTOR; GENETICS; IMMUNOTHERAPY; VIRUS;

CLINICAL TRIALS; COLORECTAL NEOPLASMS; ENZYMES; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; PRODRUGS; VIRUSES;

EID: 0041383924     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1147     Document Type: Review

References (56)

1. Ferlay, J., Bray, F., Pisani, P. & Parkin, D. M. Globocan 2000. Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No. 5. (IARC Press, Lyon, 2001).
2. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990). Excellent summary of the pattern of mutations that characterize the transition from normal colon epithelium to adenoma and then adenocarcinoma.
3. Bodmer, W. F. et al. Localisation of the gene for familial adenomatous polyposis on chromosome 5. Nature 328, 614-616 (1987).
4. Cottrell, S., Bicknell, D., Kaklamanis, L. & Bodmer, W. F. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas, Lancet 340, 626-630 (1992).
5. Midgley, R. & Kerr, D. J. Seminar in colorectal cancer. Lancet 353, 391-399 (1999). General background introduction to the natural history and modern management of colorectal cancer.
6. Douillard, J. Y. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trail. Lancet 355, 1041-1047 (2000).
7. Todryk, S. M., Chong, H., Vile, R. G., Pandha, H. & Lemoine, N. R. Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut 43, 445-449 (1998).
8. Mendelsohn, J. & Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565 (2000).
9. Papamichael, D. Prognostic role of angiogenesis in colorectal cancer. Anticancer Res. 21, 4349-4354 (2001).
10. Thompson, J. A., Grunert, F. & Zimmermann, W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J. Clin. Lab. 5, 344-366 (1999).
11. Kinzler, K. W. & Vogelstein, B. The colorectal cancer gene hunt: current findings. Hosp. Prac. 27, 51-58 (1992).
12. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorected cancer. Cell 87, 159-170 (1996).
13. Houlston, R. S. & Tomlinson, I.P.M. Polymorphisms and colorectal tumour risk. Gastroenterology 121, 282-301 (2001).
14. Harris, M. P. et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumour cells expressing mutant p53 protein. Cancer Cell Ther. 3, 121-130 (1996).
15. Opalka, B., Dickopp, A. & Kirch, H. C. Apoptotic genes in cancer therapy. Cells Tissues Organs 172, 126-132 (2002).
16. Venook, P. et al. Gene therapy of colorectal liver metastasis using recombinant adenovirus encoding wt p53 (SCH58500) via hepatic artery infusion: a phase I study. Proc. Am. Soc. Clin. Oncol. 17, 431 (1998).
17. Van Etten, B. et al. Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in that rat using an intracellular neutralizing antibody of p21-Ras. Br. J. Cancer 86, 436-442 (2002).
18. Chung-Faye, G. A. et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 8, 1547-1554 (2001).
19. Rogulski, K. R., Kim, S. H. & Freytag, S. O. Glioma cells transduced with an Echerichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. 8, 73-85 (1997).
20. Green, N. K. et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5 (aziridin-1-yl)-2, 4-dinitrobenzamide (CB 1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 4, 229-238 (1997).
21. Green, N. K. et al. Gene therapy for cancer: in vivo killing of tumour cells expressing E-coli nitroreductase following administration of the prodrug CD1954. Gene Ther. 6, 33 (1999).
22. Burrows, F. J. et al. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterisation of bystander killer mechanisms in transfected tumour cells. Cancer Gene Ther. 9, 87-95 (2002).
23. Sung, M. W. et al. Intratumoural adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol. Ther. 4, 182-191 (2001).
24. Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T. & Good, S. S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumour cells transduced with cytosine deaminase gene: significant antitumour effects when only a small percentage of tumour cells express cytosine deaminase. Proc. Natl Acad. Sci. USA 91, 8302-8306 (1994). Early demonstration of the utility of virus-directed enzyme-prodrug therapy and the importance of the bystander effect in vivo.
25. Crystal, R. G. et al. Phase I study of direct administration of replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the prodrug 5-fluorocytosine. Hum. Gene Ther. 8, 985-1001 (1997).
26. McNeish, I. A. et al. Virus directed enzyme prodrug therapy for ovarian and pancreatric cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther. 5, 1061-1069 (1998).
27. Chung-Faye, G. et al Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 7, 2662-2668 (2001).
28. Palmer, D. H. et al. Virus-directed enzyme prodrug therapy (VDEPT) clinical trials with adenoviral nitroimidazole reductase (ad-ntr). Br. J. Cancer 86, S30 (2002).
29. Chang, T. K., Weber, G. F., Crespi, C. L. & Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629-5637 (1993).
30. Marais, R., Spooner, R. A., Light, Y., Martin, J. & Springer, C. J. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56, 4735-4742 (1996).
31. Kojima, A., Hackett, N. R., Ohwada, A. & Crystal, R. G. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumours. J. Clin. Invest. 101, 1789-1796 (1998).
32. Nabel, G. J. et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl Aced. Sci. USA 90, 11307-11311 (1993).
33. Rubin, J. et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic an allogeneic histocompatability antigen, HLA-B7. Gene Ther. 4, 419-425 (1997).
34. Fakhrai, H. et al. Cytokine gene therapy with interleukin-2 transduced fibroblasts: effects of IL-2 dose on anti-tumour immunity. Hum. Gene Ther. 6, 591-601 (1995).
35. Galanis, E. et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lip complex: phase I/II experience. J. Clin. Oncol 17, 3313-3323 (1999).
36. Sobol, R. E. et al. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumour cells and genetically engineered fibroblasts: a phase I study. Clin. Cancer Res 5, 2359-2365 (1999).
37. Schmidt-Wolf, I. G. et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br. J. Cancer 81, 1009-1016 (1999).
38. Tsang, K. Y. et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine, J. Natl Cancer Inst. 87, 982-990 (1995). High-quality Phase I trial of a carcinoembryonic antigen (CEA) vaccine, showing that it was possible to detect human cytotoxic T cells specific for CEA epitopes.
39. Conry, R. M. et al. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin. Cancer Res. 5, 2330-2337 (1999).
40. Conry, R. M. et al. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin. Cancer Res. 6, 34-41 (2000).
41. Hodge, J. W., McLaughlin, J. P., Kantor, J. A. & Scholm, J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumour responses. Vaccine 15, 759-768 (1997).
42. Marshall, J. L. et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 17, 332-337 (1999).
43. Zhu, M. Z., Marshal, J., Cole, D., Scholm, J. & Tsang, K. Y. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. 6, 24-33 (2000).
44. Horig, H. et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. 49, 504-514 (2000).
45. Kirn, D. H. & McCormick, F. Replicating virus, as selective cancer therapeutics, Mol. Med. Today 2, 519-527 (1996).
46. Smith, E. R. & Chiocca, E. A. Oncolytic viruses as novel anticancer agents: turning one scourge against another. Exp. Opin. Invest. Drugs 9, 311-327 (2000).
47. Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science 274, 373-376 (1996). First description of tumour-specific replication-competent adenovirus in cancer cells with mutant TP53.
48. Reid, T. et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 8, 1618-1626 (2001).
49. Reid, T. et al. Hepatic arterial infusion of replication-selective adenovirus (dl1520): phase II viral, immunologic and clinical endpoints, Cancer Res. 62, 6070-6079 (2002).
50. Richards, C. A., Austin, E. A. & Huber, B. E. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumour-specific gene therapy. Hum. Gene Ther. 6, 881-893 (1995).
51. Bisland, A. E. et al. Selective ablation of human cancer cells by telomerase specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 22, 370-380 (2003).
52. Fisher, K. D. et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralizing antibodies. Gene Ther. 8, 341-348 (2001).
53. Maruta, F. et al. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther. 9, 543-552 (2002).
54. Benson, A. B. et al. Bevacizumab (anti-VEGF) plus FOLFOX 4 in previously treated advanced colorectal cancer patients. Proc. Am. Soc. Clin. Oncol. A39, A975 (2003).
55. Humbley, Y. et al. Cituximab alone of in combination with irinotecan in patients with epidermal growth factor receptor positive, irinotecan refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol A39, A1012 (2003).
56. Fearnhead, N. S., Wilding, J. L. & Bodmer, W. F. in Advances in Colorectal Cancer British Medical Bulletin Vol. 64 (eds Kerr, D. J., Bodmer, W. F., McArdle, C. S. & Pignatelli, M.) 27-43 (Oxford Univ. Press, Oxford, 2002).